Submit a Biologics License Application for RP1
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2023
- Due
- 31 Mar 2024
- Delivered
- November 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Biologics License Application submission anticipated in Q1/2 2024”
What we found
Evidence strength A What the grades mean
The company missed its original Q1/2 2024 deadline, subsequently updating its guidance to the second half of 2024, and ultimately submitted the BLA in November 2024.
-
A Replimune Group, Inc. 8-K filed 2024-05-16
“Recent Type C CMC meeting with the U.S. Food and Drug Administration (FDA) supports IGNYTE Biologics License Application (BLA) submission expected in 2H 2024” ✓ confirmed on the page
-
A Replimune Group, Inc. 10-Q filed 2025-02-12
“In November 2024, we announced submission of a biologics license application (BLA) to the FDA for RP1” ✓ confirmed on the page
Market reaction: the shares moved -12.8% against the S&P 500 over the three sessions around the disclosure (15 May 2024 to 20 May 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +275 days
- 4 versions
-
Version 1 · original · stated 3 Aug 2023
Deadline 31 Mar 2024 (“Q1/2 2024”) · wording expected
-
Version 2 · stated 7 Nov 2023
Deadline 30 Jun 2024 (“Q2 2024”) · wording expected
“Assuming positive data demonstrating overall clinical benefit, the Company plans to submit a Biologics License Application (BLA) for RP1 in Q2 2024.”
-
Version 3 · stated 7 Nov 2023
Deadline 30 Sep 2024 (“Q3 2024”) · wording expected
“Accordingly, the Company plans to submit the BLA in Q3 2024.”
-
Version 4 · stated 8 Feb 2024
Deadline 31 Dec 2024 (“2H 2024”) · wording expected
“biologics license application (BLA) submission expected in 2H 2024”
-
Version 5 · stated 26 Mar 2024
Deadline 31 Dec 2024 (“in 2H 2024”) · wording firm
“Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- Biologics License Application for RP1
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REPL-002714 · Corrections policy